Literature DB >> 12482823

PlA polymorphism of integrin beta 3 differentially modulates cellular migration on extracellular matrix proteins.

Mansoor Sajid1, K Vinod Vijayan, Shiloe Souza, Paul F Bray.   

Abstract

OBJECTIVE: Cell migration is central to multiple physiological and pathologic processes and involves interactions between integrins on the cell surface and the extracellular matrix. The Leu33Pro (PlA) polymorphism of integrin beta3 has been reported to be associated with a greater rate of restenosis after angioplasty, a process involving endothelial and smooth muscle cell migration. We have addressed the possibility that the Leu33Pro polymorphism could modify the migratory behavior of Chinese hamster ovary (CHO) cells expressing the beta3-containing integrin complexes. METHODS AND
RESULTS: Haptotactic migratory responses of CHO alpha(IIb)beta3 cells to fibronectin and vitronectin were not statistically different between the Leu33 and Pro33 cells. However, CHO cells with the Pro33 (PlA2) polymorphism had an enhanced haptotactic migratory response to fibrinogen and von Willebrand Factor. This enhanced migration (1) could be blocked by the alpha(IIb)beta3-complex-specific neutralizing mAb 10E5, by 7E3, a neutralizing mAb specific for the beta3 integrin, and by the alpha(IIb)beta3-blocking peptide Integrilin; (2) was not observed with a CHO cell line expressing an activating beta3 Cys435 to Ala mutation; and (3) was attributable to increased activity of mitogen-activated protein kinase and cyclooxygenase. CHO cell lines expressing the Pro33 isoform of alpha(v)beta3 had an enhanced haptotactic migratory response to vitronectin and osteopontin but not fibrinogen.
CONCLUSIONS: The Leu33Pro polymorphism alters the migratory behavior of cells on extracellular matrix substrates, and the alpha subunit influences the substrate specificity of this genetic effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482823     DOI: 10.1161/01.atv.0000043664.48689.7f

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels.

Authors:  Ana M Coutinho; Inês Sousa; Madalena Martins; Catarina Correia; Teresa Morgadinho; Celeste Bento; Carla Marques; Assunção Ataíde; Teresa S Miguel; Jason H Moore; Guiomar Oliveira; Astrid M Vicente
Journal:  Hum Genet       Date:  2007-01-03       Impact factor: 4.132

2.  Beta3 integrin haplotype influences gene regulation and plasma von Willebrand factor activity.

Authors:  Katie E Payne; Paul F Bray; Peter J Grant; Angela M Carter
Journal:  Atherosclerosis       Date:  2007-11-28       Impact factor: 5.162

3.  Variation in ITGB3 has sex-specific associations with plasma lipoprotein(a) and whole blood serotonin levels in a population-based sample.

Authors:  Lauren A Weiss; Mark Abney; Rodney Parry; Angelo M Scanu; Edwin H Cook; Carole Ober
Journal:  Hum Genet       Date:  2005-04-15       Impact factor: 4.132

4.  Replication of autism linkage: fine-mapping peak at 17q21.

Authors:  Rita M Cantor; Naoko Kono; Jackie A Duvall; Ana Alvarez-Retuerto; Jennifer L Stone; Maricela Alarcón; Stanley F Nelson; Daniel H Geschwind
Journal:  Am J Hum Genet       Date:  2005-04-01       Impact factor: 11.025

5.  The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.

Authors:  Anna Jakubowska; Dominik Rozkrut; Antonis Antoniou; Ute Hamann; Jan Lubinski
Journal:  Breast Cancer Res Treat       Date:  2009-10-30       Impact factor: 4.872

6.  Impact of hemostatic gene single point mutations in patients with non-diabetic coronary artery disease.

Authors:  Ahmet Var; Ozan Utük; Sinem Akçali; Tamer Sanlidağ; Bekir S Uyanik; Gönül Dinç
Journal:  Mol Biol Rep       Date:  2009-01-03       Impact factor: 2.316

7.  Structure of an extended β3 integrin.

Authors:  Dongwen Zhou; Aye Myat Myat Thinn; Yan Zhao; Zhengli Wang; Jieqing Zhu
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.